Welcome to EQUITY DEVELOPMENT
The UK's longest established regulated provider of sponsored equity research.
We launched EQUITY DEVELOPMENT in 1997 becoming the first ever regulated provider of Sponsored Equity Research in the UK.
Our research teams are made up of expert analysts with deep understanding & experience in their sectors. Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).
We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.
Search for Company Research
FREE REGISTRATION
Sign up today and access the very latest company research
LOG IN
For access to all company research please
York Pharma
York Pharma (YRK) is a specialty pharmaceutical company focused on the acquisition, development and commercialisation of patented, disruptive topical technology platforms that treat dermatological disorders.
Strategic acquisition
Enlarges product portfolio
Group now less reliant on approval of in-house products
Recent corporate transaction highlights significant value
Publication Date:
July 8 2008
H1 results
Significant and growing revenues reported
Derms integration going smoothly
Abasol approval expected in H2: should help a rerating
Publication Date:
May 30 2008
Perfectly placed
Speciality pharmaceutical company focused on dermatological products
A growth market benefitting from today’s environment
Strategic acquisitions in last year leave group ‘self sustaining’ with both revenues and development pipeline
Profitability likely in 2007/08, but forward multiples suggest shares are very undervalued
Publication Date:
November 30 2007